期刊文献+

西洛他唑对2型糖尿病下肢动脉病变的早期干预治疗 被引量:6

Results of Cilostazole in early treatment of arterial disease at lower extremities of type 2 daibetes
下载PDF
导出
摘要 目的 观察西洛他唑(Cilostazol CS)对2型糖尿病(T2DM)下肢动脉病变(PAD)的早期干预治疗效果及不良反应.方法 54例T2DM合并PAD早期(无伴下肢溃疡发生)患者口服CS治疗3个月,同时严格控制血糖,使糖化血红蛋白(HbAlc)控制在6.5%~7.0%,治疗前后分别检测主观症状及体征、无痛行走距离和最大行走距离、踝肱指数(ABI)、血脂、纤维蛋白原以及血小板聚集率等的变化.结果 CS治疗后,下肢疼痛明显好转,无痛行走距离和最大行走距离显著增加,ABI指数增加,纤维蛋白原与血小板聚集率降低,总胆固醇及低密度脂蛋白胆固醇降低.结论 CS通过抑制血小板聚集、扩张血管平滑肌、调解血脂等途径改善糖尿病下肢血管病变患者早期症状,延缓糖尿病足溃疡及坏疽的发生,有较好的安全性,适宜T2DM患者PAD的早期干预治疗.
出处 《中国热带医学》 CAS 2007年第8期1323-1324,共2页 China Tropical Medicine
  • 相关文献

参考文献10

二级参考文献18

  • 1畅坚,许樟荣,王志强,陈平,杨丽娜.糖尿病与非糖尿病患者外周动脉病变血管造影对比研究[J].中华糖尿病杂志(1006-6187),2004,12(5):324-327. 被引量:75
  • 2[1]Amos AF, McCarty PJ, Zimmet P. The rising global burden of diabetes and its complications. Estimates and projections to the year 2010,Diab Med,1997,7:85.
  • 3[4]Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centers:The world health organization multinational study of vascular disease in diabetics. Diabetologia. 1985,28:615~640.
  • 4[1]Ouriel K. Peripheral artery disease. Lancet , 2001, 358 :1257-1264.
  • 5[3]Diabeted drafting group. Prevalence of small and large vessel disease in diabetic patients from 14 centers. The WTO multinational study of vascular disease in diabetics. Diabetologia,1985,28(Suppl): 615-640.
  • 6[4]Jude EB, Chalmers NC, Oyibo SO, et al. Peripheral arterial disease in diabetic and nondiabetic patients - a comparison of severity and outcome. Diabetes Care, 2001,24:1433-1437.
  • 7[7]Toyata T,Hirata Y. Lipo-PGE1 ,a new lipidencapsulated preparation of prostaglandin E1 placebo and prostaglandin E1-eontrolled multi center trials in patients with diabetic neuropathy and leg ulcers. Prostaglandins, 1993,46:453.
  • 8[8]Makino H, Aoki M, Hashiya N, et al. Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by upregulation of hepatocyte growth factor. Hypertens Res, 2004,27:85-91.
  • 9[9]Mlekusch W, Schillinger M, Sabeti S, et al. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial. Vasa,2004, 33:131-136.
  • 10Yamazzki Y, Knwamum K, Yasuda H. Inhibitory effect of cilostazol on carotid hypertrophy in DM patients[J]. Yakuri to Chiryo, 1994, 21 (11): 4415.

共引文献619

同被引文献59

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部